Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
Dr. Adil Adatia, M.D., FRCPC, University of
Kusumam Joseph, Ph.D., Senior Director, Medical Affairs at Astria Therapeutics, will share information on the global Phase 3 trial of navenibart on behalf of poster authors in a presentation of a poster titled, “ALPHA-ORBIT - a Phase 3 clinical trial to evaluate the efficacy and safety of navenibart in participants with hereditary angioedema (HAE).”
Both posters will be displayed in the poster hall at the
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251009489408/en/
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.